Oncology biotech firm ZoeNCure Therapeutics has closed a ₹20 crore seed financing round led by the Tyagi family, bringing total capital raised to ₹22.5 crore. The funds will advance the company’s lead antibody‑drug conjugate (ADC) toward first‑in‑human Phase‑1 trials for hepatocellular carcinoma and gastrointestinal cancers.

  • ₹20 crore seed round led by the Tyagi family boosts total funding to ₹22.5 crore.
  • Capital earmarked for first‑in‑human Phase‑1 trials of ADC targeting HCC.
  • Investment underscores confidence in dual‑payload platform and strategic licensing.

Headquartered in New Delhi, oncology biopharma firm ZoeNCure Therapeutics announced the successful closing of a ₹20 crore seed financing round, raising its total equity to ₹22.5 crore. The round was led by the Tyagi family, with Shyambir and Manoj Tyagi spearheading the effort.

The Tyagi family previously invested ₹2.5 crore in a pre‑seed round, providing foundational support for ZoeNCure’s operations. This follow‑on capital will accelerate the company’s next‑generation antibody‑drug conjugate (ADC) program, aimed at delivering precision oncology therapies to patients with hard‑to‑treat solid tumors in India and emerging markets.

Read Also:Rupee Jumps 28 Paise Against US Dollar as Crude Oil Slides to $92

Proceeds from the seed round will fund the advancement of ZoeNCure’s lead ADC candidate toward first‑in‑human Phase‑1 clinical studies for hepatocellular carcinoma (HCC) and gastrointestinal cancers. Funding will cover preclinical studies, CMC scale‑up, and regulatory submissions to India’s Central Drugs Standard Control Organisation (CDSCO).

“We are deeply grateful for the continued trust and financial backing of the Tyagi family and our investment partners,” said ZoeNCure’s leadership team. “Securing this follow‑on capital at a critical juncture allows us to aggressively execute our preclinical and translational strategy.”

“ZoeNCure has demonstrated exceptional execution speed, scientific discipline, and capital efficiency since our initial pre‑seed investment,” said Manoj Tyagi, a representative of the Tyagi family. “Our follow‑on participation reflects our deep confidence in ZoeNCure’s leadership and its differentiated dual‑payload ADC platform.”

Building on recent strategic technology agreements, ZoeNCure is positioning itself as a pioneer in the ADC space, combining advanced antibody‑targeting platforms with dual‑mechanism cytotoxic payloads designed to overcome treatment resistance and improve patient outcomes.

Looking ahead, ZoeNCure aims to transition its ADC program from bench to bedside, delivering breakthrough therapies to patients in India and beyond. This investment marks a critical milestone in realizing the company’s vision.

Why This Matters

BozokMedia analysis shows that investment in ADC development is accelerating in India, and ZoeNCure’s funding milestone signals a positive trend for the sector.

“The dual‑payload ADC design has the potential to revolutionize treatment outcomes by mitigating resistance and enhancing efficacy.”
Did You Know?: The development of antibody‑drug conjugates began in the 1990s, but widespread clinical adoption only accelerated after 2010.

Frequently Asked Questions

1. Which cancers is ZoeNCure’s ADC program targeting? The program focuses on hepatocellular carcinoma (HCC) and gastrointestinal cancers.

2. Has the Tyagi family invested in ZoeNCure before? Yes, they previously invested ₹2.5 crore in a pre‑seed round.